welcome
therapeutics to improve cardiovascular health
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.
recent news
28 Jun 2018
Amarin Reports Last Patient Study Visit Has Occurred, an Important Step Towards Completion of REDUCE-IT™ Cardiovascular Outcomes Study MORE
25 Jun 2018
Real-World Data Supports Association Between High Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs in People with Diabetes Mellitus MORE
Stock Information
- Symbol:
- AMRN (NASDAQ)
- Quote:
- 2.80
- Change:
- +0.03
- Date:
- 4:00 PM EDT on Jul 20, 2018
Join Our Mailing List
You may automatically receive Amarin Corporation plc financial information by email.